These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32667984)

  • 21. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.
    Pitso L; Potgieter S; Van der Spoel van Dijk A
    S Afr Med J; 2019 Aug; 109(9):659-664. PubMed ID: 31635590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era.
    Beckert P; Sanchez-Padilla E; Merker M; Dreyer V; Kohl TA; Utpatel C; Köser CU; Barilar I; Ismail N; Omar SV; Klopper M; Warren RM; Hoffmann H; Maphalala G; Ardizzoni E; de Jong BC; Kerschberger B; Schramm B; Andres S; Kranzer K; Maurer FP; Bonnet M; Niemann S
    Genome Med; 2020 Nov; 12(1):104. PubMed ID: 33239092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
    J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in
    Guo Q; Bi J; Lin Q; Ye T; Wang Z; Wang Z; Liu L; Zhang G
    Front Cell Infect Microbiol; 2022; 12():807095. PubMed ID: 35694543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
    Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sub-MIC levels of bedaquiline and clofazimine can select
    Villellas C; Stevenaert F; Remmerie B; Andries K
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127523. PubMed ID: 38470194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan.
    Wu SH; Chan HH; Hsiao HC; Jou R
    Front Microbiol; 2021; 12():754249. PubMed ID: 34745058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
    Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
    Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective
    Kaniga K; Hasan R; Jou R; Vasiliauskienė E; Chuchottaworn C; Ismail N; Metchock B; Miliauskas S; Viet Nhung N; Rodrigues C; Shin S; Simsek H; Smithtikarn S; Ngoc ALT; Boonyasopun J; Kazi M; Kim S; Kamolwat P; Musteikiene G; Sacopon CA; Tahseen S; Vasiliauskaitė L; Wu MH; Vally Omar S
    J Clin Microbiol; 2022 Jan; 60(1):e0291920. PubMed ID: 34705538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Nair P; Hasan T; Zaw KK; Allamuratova S; Ismailov A; Mendonca P; Bekbaev Z; Parpieva N; Singh J; Sitali N; Bermudez-Aza E; Sinha A
    Int J Tuberc Lung Dis; 2022 Jul; 26(7):658-663. PubMed ID: 35768925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Moe S; Rekart ML; Hernandez D; Sholpan A; Ismailov A; Oluya M; Bayniyazova A; Zinaida T; Nargiza P; Gomez-Restrepo C; Sitali N; Sinha A
    Int J Tuberc Lung Dis; 2023 May; 27(5):381-386. PubMed ID: 37143220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients.
    Shang Y; Chen S; Shi W; Nie W; Jing W; Huo F; Xue Y; Dong L; Jiang G; Huang H; Chu N
    J Glob Antimicrob Resist; 2023 Jun; 33():294-300. PubMed ID: 37142094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.
    Battaglia S; Spitaleri A; Cabibbe AM; Meehan CJ; Utpatel C; Ismail N; Tahseen S; Skrahina A; Alikhanova N; Mostofa Kamal SM; Barbova A; Niemann S; Groenheit R; Dean AS; Zignol M; Rigouts L; Cirillo DM
    J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32907992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bedaquiline resistant Mycobacterium tuberculosis clinical isolates with and without rv0678 mutations have similar growth patterns under varying BDQ drug pressure.
    Saeed DK; Ashraf J; Hasan Z; Shakoor S; Kanji A; Hasan R
    Tuberculosis (Edinb); 2022 Dec; 137():102266. PubMed ID: 36195000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bedaquiline: Current status and future perspectives.
    Khoshnood S; Goudarzi M; Taki E; Darbandi A; Kouhsari E; Heidary M; Motahar M; Moradi M; Bazyar H
    J Glob Antimicrob Resist; 2021 Jun; 25():48-59. PubMed ID: 33684606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of genetic determinants of bedaquiline resistance in
    Umpeleva T; Chetverikova E; Belyaev D; Eremeeva N; Boteva T; Golubeva L; Vakhrusheva D; Vasilieva I
    Microbiol Spectr; 2024 Mar; 12(3):e0374923. PubMed ID: 38345388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
    Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
    Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
    Gao J; Gao M; Du J; Pang Y; Mao G; Lounis N; Bakare N; Jiang Y; Zhan Y; Liu Y; Li L;
    Trials; 2024 Apr; 25(1):227. PubMed ID: 38561815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.